Genentech to Present New Positive Data from Its Broad Cancer Immunotherapy Program and across a ...
– New pivotal results from the tumor-agnostic entrectinib study across a broad range of cancer types for people whose tumors have been identified as NTRK gene fusion-positive –
Read more...
More From BioPortfolio on "Genentech to Present New Positive Data from Its Broad Cancer Immunotherapy Program and across a ..."